Our pipeline

We are advancing a broad pipeline of potentially best-in-class biotherapeutics, with initial focus on immune-mediated disease. Learn more about the programs we are developing below.

Our pipeline

We are advancing a broad pipeline of potentially best-in-class biotherapeutics, with initial focus on immune-mediated disease. Learn more about the programs we are developing below.

Immunology

PROGRAM TARGET DISCOVERY IND ENABLING Phase 1
ATTO-1310 IL31

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque in dignissim dolor. Sed a ornare augue. Fusce tincidunt ut tellus et fermentum.
ATTO-002 IL31 X IL13

ATTO-004 Undisclosed bi- or tri-specific

ATTO-005 Biologically undruggable target

Immunology

PROGRAM TARGET
ATTO-1310 IL31

IND ENABLING
ATTO-002 IL31 X IL13

 IND ENABLING
ATTO-004 Undisclosed bi- or tri-specific

DISCOVERY
ATTO-005 Biologically undruggable target

DISCOVERY

Interested in partnering?

Interested in partnering?

ATTOBODIES: the binder of choice for multispecifics

ATTOBODIES are an attractive new modality for the development of bispecifics and multispecifics. We are open to collaborations exploring the potential of our ATTOBODIES to enrich and improve our partners’ development pipelines and discovery efforts.